Titre : Complement C3-C5 Convertases

Complement C3-C5 Convertases : Questions médicales fréquentes

Termes MeSH sélectionnés :

Complement System Proteins
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Complement C3-C5 Convertases : Questions médicales les plus fréquentes", "headline": "Complement C3-C5 Convertases : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Complement C3-C5 Convertases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-03-14", "dateModified": "2025-03-09", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Complement C3-C5 Convertases" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Enzymes activatrices du complément", "url": "https://questionsmedicales.fr/mesh/D003166", "about": { "@type": "MedicalCondition", "name": "Enzymes activatrices du complément", "code": { "@type": "MedicalCode", "code": "D003166", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.124.486.274.045" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Alternative pathway C3-C5 Convertases", "alternateName": "Complement C3-C5 Convertases, Alternative Pathway", "url": "https://questionsmedicales.fr/mesh/D050578", "about": { "@type": "MedicalCondition", "name": "Alternative pathway C3-C5 Convertases", "code": { "@type": "MedicalCode", "code": "D050578", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.124.486.274.045.387.500" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Alternative pathway complement C3 convertase", "alternateName": "Complement C3 Convertase, Alternative Pathway", "url": "https://questionsmedicales.fr/mesh/D051561", "about": { "@type": "MedicalCondition", "name": "Alternative pathway complement C3 convertase", "code": { "@type": "MedicalCode", "code": "D051561", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.124.486.274.045.387.500.374" } } }, { "@type": "MedicalWebPage", "name": "Alternative pathway C5 convertase", "alternateName": "Complement C5 Convertase, Alternative Pathway", "url": "https://questionsmedicales.fr/mesh/D051566", "about": { "@type": "MedicalCondition", "name": "Alternative pathway C5 convertase", "code": { "@type": "MedicalCode", "code": "D051566", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.124.486.274.045.387.500.750" } } } ] }, { "@type": "MedicalWebPage", "name": "Classical pathway C3-C5 Convertases", "alternateName": "Complement C3-C5 Convertases, Classical Pathway", "url": "https://questionsmedicales.fr/mesh/D050579", "about": { "@type": "MedicalCondition", "name": "Classical pathway C3-C5 Convertases", "code": { "@type": "MedicalCode", "code": "D050579", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.124.486.274.045.387.750" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Classical pathway complement C3 convertase", "alternateName": "Complement C3 Convertase, Classical Pathway", "url": "https://questionsmedicales.fr/mesh/D051574", "about": { "@type": "MedicalCondition", "name": "Classical pathway complement C3 convertase", "code": { "@type": "MedicalCode", "code": "D051574", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.124.486.274.045.387.750.500" } } }, { "@type": "MedicalWebPage", "name": "Classical pathway C5 convertase", "alternateName": "Complement C5 Convertase, Classical Pathway", "url": "https://questionsmedicales.fr/mesh/D051577", "about": { "@type": "MedicalCondition", "name": "Classical pathway C5 convertase", "code": { "@type": "MedicalCode", "code": "D051577", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.124.486.274.045.387.750.750" } } } ] }, { "@type": "MedicalWebPage", "name": "Mannose-Binding Protein-Associated Serine Proteases", "alternateName": "Mannose-Binding Protein-Associated Serine Proteases", "url": "https://questionsmedicales.fr/mesh/D050606", "about": { "@type": "MedicalCondition", "name": "Mannose-Binding Protein-Associated Serine Proteases", "code": { "@type": "MedicalCode", "code": "D050606", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.124.486.274.045.387.875" } } } ], "about": { "@type": "MedicalCondition", "name": "Complement C3-C5 Convertases", "alternateName": "Complement C3-C5 Convertases", "code": { "@type": "MedicalCode", "code": "D050577", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "John D Lambris", "url": "https://questionsmedicales.fr/author/John%20D%20Lambris", "affiliation": { "@type": "Organization", "name": "Department of Laboratory Medicine and Pathology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA." } }, { "@type": "Person", "name": "Tom Eirik Mollnes", "url": "https://questionsmedicales.fr/author/Tom%20Eirik%20Mollnes", "affiliation": { "@type": "Organization", "name": "Research Laboratory, Nordland Hospital, 8092 Bodø, Norway." } }, { "@type": "Person", "name": "Dimitrios C Mastellos", "url": "https://questionsmedicales.fr/author/Dimitrios%20C%20Mastellos", "affiliation": { "@type": "Organization", "name": "National Center for Scientific Research 'Demokritos', Athens, Greece." } }, { "@type": "Person", "name": "Giuseppe Remuzzi", "url": "https://questionsmedicales.fr/author/Giuseppe%20Remuzzi", "affiliation": { "@type": "Organization", "name": "Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy." } }, { "@type": "Person", "name": "Markus Huber-Lang", "url": "https://questionsmedicales.fr/author/Markus%20Huber-Lang", "affiliation": { "@type": "Organization", "name": "Institute of Clinical and Experimental Trauma Immunology, University Hospital of Ulm, Ulm, Germany." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Urinary complement proteins in IgA nephropathy progression from a relative quantitative proteomic analysis.", "datePublished": "2023-04-11", "url": "https://questionsmedicales.fr/article/37065697", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.7717/peerj.15125" } }, { "@type": "ScholarlyArticle", "name": "Relationship between the complement system and serum lipid profile in patients with rheumatoid arthritis.", "datePublished": "2024-07-12", "url": "https://questionsmedicales.fr/article/39072319", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fimmu.2024.1420292" } }, { "@type": "ScholarlyArticle", "name": "The Relationship between the complement system and subclinical carotid atherosclerosis in patients with rheumatoid arthritis.", "datePublished": "2024-07-08", "url": "https://questionsmedicales.fr/article/38978073", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s13075-024-03360-3" } }, { "@type": "ScholarlyArticle", "name": "The Contribution of Complement Protein C1q in COVID-19 and HIV Infection Comorbid with Preeclampsia: A Review.", "datePublished": "2022-06-03", "url": "https://questionsmedicales.fr/article/35661665", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1159/000524976" } }, { "@type": "ScholarlyArticle", "name": "Elevated plasma complement factor H related 5 protein is associated with venous thromboembolism.", "datePublished": "2023-06-07", "url": "https://questionsmedicales.fr/article/37286573", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41467-023-38383-y" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines du sang", "item": "https://questionsmedicales.fr/mesh/D001798" }, { "@type": "ListItem", "position": 5, "name": "Immunoprotéines", "item": "https://questionsmedicales.fr/mesh/D007162" }, { "@type": "ListItem", "position": 6, "name": "Protéines du système du complément", "item": "https://questionsmedicales.fr/mesh/D003165" }, { "@type": "ListItem", "position": 7, "name": "Enzymes activatrices du complément", "item": "https://questionsmedicales.fr/mesh/D003166" }, { "@type": "ListItem", "position": 8, "name": "Complement C3-C5 Convertases", "item": "https://questionsmedicales.fr/mesh/D050577" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Complement C3-C5 Convertases - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Complement C3-C5 Convertases", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-12", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Complement C3-C5 Convertases", "description": "Comment diagnostiquer une déficience en convertases C3-C5 ?\nQuels tests sont utilisés pour évaluer l'activité du complément ?\nQuels signes cliniques suggèrent une activation du complément ?\nPeut-on mesurer l'activité des convertases dans le sang ?\nQuels marqueurs biologiques sont associés aux convertases ?", "url": "https://questionsmedicales.fr/mesh/D050577?mesh_terms=Complement+System+Proteins&page=4#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Complement C3-C5 Convertases", "description": "Quels symptômes indiquent une activation excessive du complément ?\nComment se manifestent les troubles liés aux convertases ?\nLes troubles du complément causent-ils des symptômes neurologiques ?\nQuels signes indiquent une déficience en C3 ?\nLes symptômes varient-ils selon le type de déficience ?", "url": "https://questionsmedicales.fr/mesh/D050577?mesh_terms=Complement+System+Proteins&page=4#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Complement C3-C5 Convertases", "description": "Peut-on prévenir les déficiences en complément ?\nQuelles mesures préventives peuvent réduire les infections ?\nLes patients doivent-ils éviter certains aliments ?\nComment le suivi médical aide-t-il à prévenir les complications ?\nLes conseils génétiques sont-ils utiles pour les familles ?", "url": "https://questionsmedicales.fr/mesh/D050577?mesh_terms=Complement+System+Proteins&page=4#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Complement C3-C5 Convertases", "description": "Quels traitements sont disponibles pour les déficiences en complément ?\nComment traiter une activation excessive du complément ?\nLes transfusions sanguines aident-elles en cas de déficience ?\nY a-t-il des thérapies géniques pour les déficiences en complément ?\nLes traitements sont-ils personnalisés selon le patient ?", "url": "https://questionsmedicales.fr/mesh/D050577?mesh_terms=Complement+System+Proteins&page=4#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Complement C3-C5 Convertases", "description": "Quelles complications peuvent survenir avec une déficience en C3 ?\nLes complications sont-elles réversibles ?\nComment les complications affectent-elles la qualité de vie ?\nLes complications neurologiques sont-elles fréquentes ?\nQuelles sont les complications liées à l'activation excessive du complément ?", "url": "https://questionsmedicales.fr/mesh/D050577?mesh_terms=Complement+System+Proteins&page=4#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Complement C3-C5 Convertases", "description": "Quels facteurs augmentent le risque de déficience en complément ?\nL'âge influence-t-il le risque de troubles du complément ?\nLes infections fréquentes sont-elles un facteur de risque ?\nLe sexe joue-t-il un rôle dans les troubles du complément ?\nLes maladies génétiques augmentent-elles le risque ?", "url": "https://questionsmedicales.fr/mesh/D050577?mesh_terms=Complement+System+Proteins&page=4#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une déficience en convertases C3-C5 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins mesurant les niveaux de C3 et C5 peuvent indiquer une déficience." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'activité du complément ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests d'hémolyse et les dosages de protéines du complément sont courants." } }, { "@type": "Question", "name": "Quels signes cliniques suggèrent une activation du complément ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme des infections récurrentes ou des maladies auto-immunes peuvent indiquer une activation." } }, { "@type": "Question", "name": "Peut-on mesurer l'activité des convertases dans le sang ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des tests spécifiques peuvent évaluer l'activité des convertases dans le sérum." } }, { "@type": "Question", "name": "Quels marqueurs biologiques sont associés aux convertases ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Les niveaux de C3a et C5a, produits de clivage, sont des marqueurs importants." } }, { "@type": "Question", "name": "Quels symptômes indiquent une activation excessive du complément ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme des éruptions cutanées, des douleurs articulaires et de la fièvre peuvent survenir." } }, { "@type": "Question", "name": "Comment se manifestent les troubles liés aux convertases ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent se manifester par des infections fréquentes et des réactions inflammatoires." } }, { "@type": "Question", "name": "Les troubles du complément causent-ils des symptômes neurologiques ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des troubles neurologiques peuvent survenir en raison d'une inflammation cérébrale." } }, { "@type": "Question", "name": "Quels signes indiquent une déficience en C3 ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des infections bactériennes récurrentes et des maladies auto-immunes peuvent être des signes." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon le type de déficience ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent varier selon que la déficience concerne C3 ou C5." } }, { "@type": "Question", "name": "Peut-on prévenir les déficiences en complément ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention est difficile, mais un diagnostic précoce peut aider à gérer les symptômes." } }, { "@type": "Question", "name": "Quelles mesures préventives peuvent réduire les infections ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Des vaccinations et une bonne hygiène peuvent aider à réduire le risque d'infections." } }, { "@type": "Question", "name": "Les patients doivent-ils éviter certains aliments ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Il n'y a pas de restrictions alimentaires spécifiques, mais une alimentation équilibrée est conseillée." } }, { "@type": "Question", "name": "Comment le suivi médical aide-t-il à prévenir les complications ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Un suivi régulier permet d'identifier et de traiter rapidement les complications potentielles." } }, { "@type": "Question", "name": "Les conseils génétiques sont-ils utiles pour les familles ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les conseils génétiques peuvent aider à comprendre les risques de transmission." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour les déficiences en complément ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent des immunoglobulines intraveineuses et des antibiotiques prophylactiques." } }, { "@type": "Question", "name": "Comment traiter une activation excessive du complément ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments anti-inflammatoires et des inhibiteurs du complément peuvent être utilisés." } }, { "@type": "Question", "name": "Les transfusions sanguines aident-elles en cas de déficience ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les transfusions peuvent aider à restaurer les niveaux de protéines du complément." } }, { "@type": "Question", "name": "Y a-t-il des thérapies géniques pour les déficiences en complément ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Des recherches sont en cours sur les thérapies géniques pour traiter ces déficiences." } }, { "@type": "Question", "name": "Les traitements sont-ils personnalisés selon le patient ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements sont souvent adaptés en fonction des besoins individuels du patient." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec une déficience en C3 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des infections graves, des maladies auto-immunes et des complications rénales peuvent survenir." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes." } }, { "@type": "Question", "name": "Comment les complications affectent-elles la qualité de vie ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent réduire la qualité de vie en entraînant des douleurs chroniques et des limitations fonctionnelles." } }, { "@type": "Question", "name": "Les complications neurologiques sont-elles fréquentes ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des complications neurologiques peuvent survenir, notamment des troubles cognitifs." } }, { "@type": "Question", "name": "Quelles sont les complications liées à l'activation excessive du complément ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme des lésions tissulaires et des réactions inflammatoires peuvent se produire." } }, { "@type": "Question", "name": "Quels facteurs augmentent le risque de déficience en complément ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Des antécédents familiaux et certaines maladies auto-immunes augmentent le risque." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque de troubles du complément ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le risque peut augmenter avec l'âge en raison de la dégradation du système immunitaire." } }, { "@type": "Question", "name": "Les infections fréquentes sont-elles un facteur de risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des infections fréquentes peuvent indiquer une déficience sous-jacente du complément." } }, { "@type": "Question", "name": "Le sexe joue-t-il un rôle dans les troubles du complément ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines déficiences sont plus fréquentes chez les femmes en raison de facteurs hormonaux." } }, { "@type": "Question", "name": "Les maladies génétiques augmentent-elles le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines maladies génétiques peuvent prédisposer à des déficiences du complément." } } ] } ] }

Sources (10000 au total)

Urinary complement proteins in IgA nephropathy progression from a relative quantitative proteomic analysis.

IgA nephropathy (IgAN) is one of the leading causes of end-stage renal disease (ESRD). Urine testing is a non-invasive way to track the biomarkers used for measuring renal injury. This study aimed to ... In the discovery phase, we analysed 22 IgAN patients who were divided into three groups (IgAN 1-3) according to their estimated glomerular filtration rate (eGFR). Eight patients with primary membranou... In the discovery phase, 747 proteins were identified in the urine of IgAN and pMN patients. There were different urine protein profiles in IgAN and pMN patients, and the bioinformatics analysis reveal... There were abundant complement components in the urine of IgAN patients, indicating that the activation of AP and LP is involved in IgAN progression. Urinary complement proteins may be used as biomark...

Relationship between the complement system and serum lipid profile in patients with rheumatoid arthritis.

The complement system has been linked to the etiopathogenesis of rheumatoid arthritis (RA). Patients with RA exhibit a dysregulated profile of lipid molecules, which has been attributed to the inflamm... 430 patients with RA were recruited. New-generation techniques were employed to conduct functional assays of the three pathways of the complement system. Serum levels of various complement components ... After multivariable analysis, several noteworthy associations emerged between the complement system and lipid molecules. Notably, complement components most strongly linked to the lipid profile were C... The correlation between the complement system and lipid molecule patterns is pronounced in patients with RA. This relationship is predominantly positive and primarily associated with upstream compleme...

The Relationship between the complement system and subclinical carotid atherosclerosis in patients with rheumatoid arthritis.

Patients with rheumatoid arthritis (RA) have an increased risk of cardiovascular (CV) events and CV mortality. Subclinical carotid atherosclerosis is independently associated with rates of incident CV... 430 patients with RA were recruited. Functional assays of the three pathways of the complement system, utilizing new-generation techniques, were assessed. Additionally, serum levels of individual comp... After multivariable adjustment, which included traditional CV risk factors and disease-related data, C3a and C5a exhibited significant positive correlations with carotid intima media thickness. Additi... The complement system and subclinical carotid atherosclerosis are linked in patients with RA....

The complement system in antineutrophil cytoplasmic antibody-associated vasculitis: pathogenic player and therapeutic target.

The purpose of this review is to discuss the role of the complement system in the pathogenesis of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) as well as the employment of co... AAV has traditionally been considered a pauci-immune disease until recent findings demonstrated the pathogenic role of the complement system. The complement alternative pathway is crucial in AAV, and ... The increased circulating levels of some complement components - as well as the consumption of others - in patients with AAV suggested a systemic activation of the complement system. Low C3 levels cor...

Elevated CSF and plasma complement proteins in genetic frontotemporal dementia: results from the GENFI study.

Neuroinflammation is emerging as an important pathological process in frontotemporal dementia (FTD), but biomarkers are lacking. We aimed to determine the value of complement proteins, which are key c... We measured the complement proteins C1q and C3b in CSF by ELISAs in 224 presymptomatic and symptomatic GRN, C9orf72 or MAPT mutation carriers and non-carriers participating in the Genetic Frontotempor... CSF C1q and C3b, as well as plasma C2 and C3, were elevated in symptomatic mutation carriers compared to presymptomatic carriers and non-carriers. In genetic subgroup analyses, these differences remai... Elevated levels of CSF C1q and C3b, as well as plasma C2 and C3, demonstrate the presence of complement activation in the symptomatic stage of genetic FTD. Intriguingly, correlations with several dise...